Mitsubishi UFJ Kokusai Asset Management Co. Ltd. reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 18.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 196,104 shares of the medical equipment provider’s stock after selling 44,135 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Boston Scientific Corporation were worth $5,436,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Quadrant Capital Group LLC boosted its stake in shares of Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock worth $122,000 after buying an additional 487 shares during the period. National Pension Service boosted its stake in shares of Boston Scientific Corporation by 0.6% in the first quarter. National Pension Service now owns 1,058,667 shares of the medical equipment provider’s stock worth $25,884,000 after buying an additional 6,634 shares during the period. Bank of Montreal Can boosted its stake in shares of Boston Scientific Corporation by 2.3% in the first quarter. Bank of Montreal Can now owns 511,136 shares of the medical equipment provider’s stock worth $12,711,000 after buying an additional 11,611 shares during the period. Private Wealth Partners LLC boosted its stake in shares of Boston Scientific Corporation by 3.4% in the first quarter. Private Wealth Partners LLC now owns 207,266 shares of the medical equipment provider’s stock worth $5,155,000 after buying an additional 6,796 shares during the period. Finally, DnB Asset Management AS boosted its stake in shares of Boston Scientific Corporation by 12.3% in the first quarter. DnB Asset Management AS now owns 137,750 shares of the medical equipment provider’s stock worth $3,426,000 after buying an additional 15,100 shares during the period. 92.08% of the stock is owned by institutional investors.

Shares of Boston Scientific Corporation (BSX) opened at 26.26 on Friday. The firm has a market cap of $36.03 billion, a P/E ratio of 46.98 and a beta of 1.09. The firm’s 50-day moving average price is $27.38 and its 200 day moving average price is $26.02. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the company posted $0.27 earnings per share. Boston Scientific Corporation’s revenue was up 6.2% compared to the same quarter last year. Analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/11/boston-scientific-corporation-nysebsx-position-decreased-by-mitsubishi-ufj-kokusai-asset-management-co-ltd.html.

BSX has been the subject of a number of recent analyst reports. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, April 24th. TheStreet raised Boston Scientific Corporation from a “c+” rating to a “b” rating in a research note on Tuesday, April 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target (up from $29.00) on shares of Boston Scientific Corporation in a research note on Thursday, April 27th. Oppenheimer Holdings, Inc. set a $27.00 target price on Boston Scientific Corporation and gave the stock a “hold” rating in a research note on Friday, April 28th. Finally, Evercore ISI increased their target price on Boston Scientific Corporation from $26.50 to $28.50 and gave the stock an “outperform” rating in a research note on Friday, April 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Boston Scientific Corporation presently has a consensus rating of “Buy” and an average price target of $30.06.

In other Boston Scientific Corporation news, SVP Wendy Carruthers sold 12,433 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $26.75, for a total value of $332,582.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Daniel J. Brennan sold 92,158 shares of the company’s stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total value of $2,532,501.84. Following the completion of the transaction, the chief financial officer now owns 235,421 shares of the company’s stock, valued at approximately $6,469,369.08. The disclosure for this sale can be found here. Insiders sold a total of 236,489 shares of company stock valued at $6,440,888 in the last 90 days. Corporate insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.